RNAC vs. RLMD, NVCT, SCTL, ELYM, IMUX, RPTX, CTMX, AMLX, PDSB, and RZLT
Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Relmada Therapeutics (RLMD), Nuvectis Pharma (NVCT), Societal CDMO (SCTL), Eliem Therapeutics (ELYM), Immunic (IMUX), Repare Therapeutics (RPTX), CytomX Therapeutics (CTMX), Amylyx Pharmaceuticals (AMLX), PDS Biotechnology (PDSB), and Rezolute (RZLT). These companies are all part of the "pharmaceutical preparations" industry.
Relmada Therapeutics (NASDAQ:RLMD) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends.
In the previous week, Cartesian Therapeutics had 27 more articles in the media than Relmada Therapeutics. MarketBeat recorded 29 mentions for Cartesian Therapeutics and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.74 beat Cartesian Therapeutics' score of 0.53 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.
Relmada Therapeutics has a net margin of 0.00% compared to Relmada Therapeutics' net margin of -845.01%. Relmada Therapeutics' return on equity of -58.21% beat Cartesian Therapeutics' return on equity.
Relmada Therapeutics received 10 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cartesian Therapeutics an outperform vote while only 41.03% of users gave Relmada Therapeutics an outperform vote.
Relmada Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.
Relmada Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 552.74%. Cartesian Therapeutics has a consensus price target of $45.00, indicating a potential upside of 113.98%. Given Cartesian Therapeutics' higher probable upside, equities analysts plainly believe Relmada Therapeutics is more favorable than Cartesian Therapeutics.
45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 13.5% of Relmada Therapeutics shares are held by insiders. Comparatively, 31.2% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Relmada Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics.
Summary
Cartesian Therapeutics beats Relmada Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Cartesian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cartesian Therapeutics Competitors List
Related Companies and Tools
